Prognostic Value of Pretreated Blood Inflammatory Markers in Patients with Bone Sarcoma: A Meta-Analysis

Table 1

Basic characteristic of included study.

Author	Year	Country	Sample size	Stage	Cutoff value	Markers	Outcome	Histology type	Analysis method	NOS score
Yang et al.	2020	China	133	Mixed	2.96; 4.44	NLR, LMR	OS, PFS	Osteosarcoma	MA	8
Xu et al.	2019	China	150	Mixed	2.7; 200	NLR, PLR	OS, DFS	Chondrosarcoma	MA	8
Huang et al.	2019	China	126	Mixed	2.1; 163.2	NLR, PLR	OS	Osteosarcoma	MA	7
Li et al.	2017	China	122	Mixed	2.38; 131; 4.41	NLR, PLR; LMR	OS	Ewing sarcoma	UA	7
Vasquez et al.	2017	Peru	78	Mixed	2; 150	NLR, PLR	OS	Osteosarcoma; Ewing sarcoma	UA; MA	6
Li et al.	2017	China	216	Mixed	2.65; 118	NLR, PLR	OS	Osteosarcoma	UA	7
Xia et al.	2016	China	359	Mixed	3.43; 122	NLR, PLR	OS, PFS	Osteosarcoma	MA	7
Liu et al.	2016	China	162	Mixed	2.57; 123.5; 4.73	NLR, PLR; LMR	OS	Osteosarcoma	MA	7
Ninna et al.	2016	Denmark	172	Nonmetastatic	5.3	NLR	OS	Osteosarcoma; Ewing sarcoma; Chondrosarcoma	MA	8
Liu et al.	2015	China	327	Mixed	3.43	LMR	OS, EFS	Osteosarcoma	MA	8

Abbreviations: NLR: neutrophil lymphocyte ratio; PLR: platelet lymphocyte ratio; LMR: lymphocyte monocyte ratio; OS: overall survival; PFS: progression-free survival; DFS: disease-free survival; EFS: event-free survival, MA: multivariate analysis; UA: univariate analysis.